Birdwatch Note
2024-04-30 06:40:35 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Every drug and vaccine have side effects. Covishield has a very low death rate of 1 per million. Calling it a poison is over- exaggeration and misinterpretation. Source: https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca
Written by 1ADCA3064F5D8E9AEFF940766D8D769A9F868A6FEAA7C51DF624EEA991E00630
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1785171636674547757
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1785197538754138216
- noteId - 1785197538754138216
- participantId -
- noteAuthorParticipantId - 1ADCA3064F5D8E9AEFF940766D8D769A9F868A6FEAA7C51DF624EEA991E00630 Participant Details
- createdAtMillis - 1714459235262
- tweetId - 1785171636674547757
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Every drug and vaccine have side effects. Covishield has a very low death rate of 1 per million. Calling it a poison is over- exaggeration and misinterpretation. Source: https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2024-04-30 06:40:35 UTC (1714459235262) |
2024-04-30 11:51:14 UTC (1714477874726) |
CURRENTLY_RATED_HELPFUL | 2024-05-01 12:35:12 UTC (1714566912495) |
CURRENTLY_RATED_HELPFUL | 2024-04-30 11:51:14 UTC (1714477874726) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
rated at | rated by | |
2024-04-30 09:45:57 -0500 | Rating Details | |
2024-04-30 09:44:36 -0500 | Rating Details | |
2024-04-30 06:50:00 -0500 | Rating Details | |
2024-04-30 06:46:38 -0500 | Rating Details | |
2024-04-30 05:18:10 -0500 | Rating Details | |
2024-04-30 05:02:21 -0500 | Rating Details | |
2024-04-30 04:29:10 -0500 | Rating Details | |
2024-04-30 03:17:18 -0500 | Rating Details | |
2024-04-30 03:12:19 -0500 | Rating Details | |
2024-04-30 03:07:51 -0500 | Rating Details | |
2024-04-30 02:23:46 -0500 | Rating Details | |
2024-04-30 02:18:57 -0500 | Rating Details | |
2024-04-30 02:03:23 -0500 | Rating Details | |
2024-04-30 21:15:33 -0500 | Rating Details | |
2024-04-30 20:55:23 -0500 | Rating Details | |
2024-05-01 04:26:18 -0500 | Rating Details | |
2024-04-30 04:24:52 -0500 | Rating Details | |
2024-04-30 04:07:05 -0500 | Rating Details | |
2024-04-30 02:26:00 -0500 | Rating Details | |
2024-04-30 02:16:05 -0500 | Rating Details | |
2024-04-30 02:10:35 -0500 | Rating Details | |
2024-04-30 01:48:18 -0500 | Rating Details | |
2024-04-30 01:46:14 -0500 | Rating Details | |
2024-04-30 01:41:34 -0500 | Rating Details | |
2024-04-30 22:13:29 -0500 | Rating Details | |
2024-04-30 15:33:05 -0500 | Rating Details | |
2024-04-30 14:20:03 -0500 | Rating Details | |
2024-04-30 12:25:22 -0500 | Rating Details | |
2024-04-30 09:59:12 -0500 | Rating Details | |
2024-04-30 09:29:46 -0500 | Rating Details | |
2024-04-30 07:58:17 -0500 | Rating Details | |
2024-04-30 04:36:20 -0500 | Rating Details | |
2024-04-30 03:08:47 -0500 | Rating Details | |
2024-04-30 02:35:28 -0500 | Rating Details | |
2024-04-30 02:18:42 -0500 | Rating Details | |
2024-04-30 02:07:31 -0500 | Rating Details | |
2024-04-30 02:06:45 -0500 | Rating Details | |
2024-04-30 01:59:36 -0500 | Rating Details | |
2024-04-30 23:16:24 -0500 | Rating Details | |
2024-04-30 14:59:57 -0500 | Rating Details | |
2024-04-30 14:35:27 -0500 | Rating Details | |
2024-04-30 10:30:24 -0500 | Rating Details | |
2024-04-30 09:57:10 -0500 | Rating Details | |
2024-04-30 09:27:34 -0500 | Rating Details | |
2024-04-30 04:09:10 -0500 | Rating Details | |
2024-04-30 03:44:27 -0500 | Rating Details | |
2024-04-30 03:37:05 -0500 | Rating Details | |
2024-04-30 03:34:20 -0500 | Rating Details | |
2024-04-30 02:34:50 -0500 | Rating Details | |
2024-04-30 02:19:37 -0500 | Rating Details | |
2024-04-30 02:01:54 -0500 | Rating Details | |
2024-04-30 01:45:20 -0500 | Rating Details | |
2024-04-30 04:08:05 -0500 | Rating Details | |
2024-04-30 03:50:07 -0500 | Rating Details | |
2024-04-30 03:36:58 -0500 | Rating Details | |
2024-04-30 02:13:06 -0500 | Rating Details |